Factors Influencing Taiwanese Community Elders to Receive Influenza Vaccination - What Strategy We Can Have for the Goal of High Vaccination Rate?  by Jhao, W.S. et al.
13th International Congress on Infectious Diseases Abstracts, Poster Presentations e145
subjects previously exposed to MDV or YFV had higher neu-
tralizing responses than na¨ıve subjects.
Conclusions: Prior exposure to YF vaccination or live,
attenuated dengue vaccine virus, did not adversely affect
the safety and viremia proﬁle of a this recombinant, live
attenuated tetravalent dengue vaccine, and appeared to
increase immunogenicity.
doi:10.1016/j.ijid.2008.05.360
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Background and objectives: Haemophilus inﬂuenzae type
b (Hib) vaccination is not a routine immunization service in
Korea yet. This study was performed to estimate the disease
burden of Hib and the cost-beneﬁt of providing Hib vaccine
to children in Korea.
Method: We used the Rapid Assessment Tools (RATs) of
WHO to estimate the pre-vaccination Hib incidence and mor-
tality; one based on meningitis incidence in community and
the other based on under 5 year mortality statistics in 2004.
The fatality and sequelaes of Hib diseases were obtained
from multi-center based registry data. The direct and indi-
rect cost of Hib were calculated from the National Health
Insurance data (hospitalization and outpatient cost) in 2004,
National Health and Nutrition Survey(transport cost to hos-
pitals), Report of Ministry of Labor (indirect cost of work loss
and death) in 2004. Sensitivity analysis was done.
Results: The annual incidence of Hib meningitis was
10.8(95% CI: 3.8—15.0) per 100,000 children <5 years and
the case fatality rate was 6%. The average treatment cost
for an Hib meningitis case was about US $ 2,157. For a fatal
case, the average life time discounted economic loss was
about US $ 849,085. The Total annual cost of Hib diseases
was about US $ 42.5million. The break-even vaccine price,
where the annual vaccination costs equal annual Hib disease
burden averted was US $ 23.3 per dose in base case scenario
with 3% discount rate. In sensitivity analysis, due to the wide
conﬁdence interval of meningitis incidence rate, the burden
of Hib was from 15.9million to 58.6million.
Conclusion: In base case scenario, the routine Hib vacci-
nation to children would be cost-beneﬁt in Korea.
doi:10.1016/j.ijid.2008.05.361
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Background: In Taiwan, average inﬂuenza associated
mortality is approximately 4,500 per year. Inﬂuenza vacci-
nation is the most effective method to prevent inﬂuenza
infection and reduce its potentially severe complications.
In 1997, Taiwan launched the inﬂuenza vaccination cam-
paign. Since 1998, the government continually provides free
inﬂuenza vaccines to elderly aged 65 and above and other
high risk groups. The purpose of this article is to assess the
effectiveness of inﬂuenza vaccination in the elderly.
Method: For this retrospective observational study, vac-
cination coverage was collected through weekly based
reporting system and data regarding medical attendance
was retrieved from National Health Insurance databank from
1998 to 2007 inﬂuenza seasons. Medical attendance rate and
hospitalization rate was adjusted by age according to 2000
world standard.
Results: Inﬂuenza vaccination coverage among elderly
ranged from 9.9% to 68.4% with the peak in 2003. The annual
hospitalization rate (per 1,000 population) declined steadily
from 33.1 in 1998 to 28.8 in 2000, but rebounded slightly
from 30.8 in 2001 to 38.4 in 2005. The annual medical atten-
dance rate (per 1,000 population) declined from 202.2 in
1998 to 75.8 in 2006.The correlation analysis was height
relation (r = 0.7) between coverage and medical attendance
rat.
Conclusion: The declining medical attendance rate
attributes to vaccination upholds the inﬂuenza vaccination
program for the elderly. There is no evidence that inﬂuenza
vaccination is effective in reducing hospitalization in the
elderly. But it could be due to the National Health Insurance
confers full accessibility to the medical resources. As the
inﬂuenza vaccination coverage among elderly declines year
by year, a more aggressive and comprehensive educational
promotion strategy should be enhanced.
doi:10.1016/j.ijid.2008.05.362
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Nearly 4,500 persons die of inﬂuenza and related com-
plication yearly in Taiwan (20 /100,000 population), 80% of
them is 65 years or older. Policy of providing free inﬂuenza
vaccination for all people aged 65 and older started from
2001, but vaccination rates remained low with decreasing
trend. Understanding the relevant factors of inﬂuenza vac-
cination would be helpful for the vaccination strategy.
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Two telephone surveys were conducted during October
3—11 and December 15—17, 2007 targeting people aged
65 and older randomly sampled by the Computer Assisted
Telephone Interview (CATI). Questionnaires were developed
under the theoretical framework of the health belief model.
Among 1,115 effective samples of pre-survey, 512 (45.9%)
were successfully followed.
512 people of post-survey were representative of
pre-survey population because of their comparability of
demographic characteristics. 62.6% (698/1,115) expressed
their willingness to receive vaccination and 61.0% (312/512)
among post-survey samples actually received vaccina-
tion. Important factors inﬂuencing their willingness were
their beneﬁcial belief in vaccination (OR = 19.8, 95%
CI = 10.0—39.2), with obstacles of vaccination (OR = 8.0, 95%
CI = 5.0—12.7), awareness of disease seriousness (OR = 1.9,
95% CI = 1.2—3.0). The relevant factors for actual vac-
cination were living with chronic disease (OR = 2.2, 95%
CI = 1.1—4.1), fear of contracting inﬂuenza (OR = 3.2,
95%CI = 1.8—5.8, fear of health impairment OR = 3.3, 95%
CI = 1.7—6.7, fear of adverse effects of vaccination (OR = 0.2,
95% CI = 0.1—0.3) and unawareness of disease threat
(OR = 0.5, 95% CI = 0.30.9).
The rate of willingness, approximately to the actual
rate of vaccination, and the similar attitude and beliefs
on inﬂuenza vaccination between two survey population
demonstrate the difﬁculty of conducting propaganda for
the elderly. However, target-oriented, focusing relevant fac-
tors and selecting appropriate media channels would be the
solution for the challenge of high vaccination rate of the
elderly.
doi:10.1016/j.ijid.2008.05.363
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Children suffer severe effects of inﬂuenza and play a
major role in disease transmission. Therefore prepandemic
inﬂuenza vaccination of children may be a highly effective
measure to contain the spread of pandemic inﬂuenza and to
reduce its morbidity and mortality.
This pediatric study (107066/NCT00502593) evaluated
the safety of two administrations, 21 days apart, of an
H5N1 split virus inﬂuenza vaccine containing 1.9g HA
(A/Vietnam/1194/2004) adjuvanted with an oil-in-water
emulsion-based Adjuvant System (H5N1/AS group) as com-
pared to immunizations with the non-adjuvanted seasonal
inﬂuenza vaccine FluarixTM (control) marketed by Glax-
oSmithKline. For this partial preliminary analysis, 138
children aged 3—9 years completed the safety evaluation
(H5N1/AS-[3—5y]:N = 51, (H5N1/AS-[6—9y]:N = 51, Control-
[3—5y]:N = 18; Control-[6—9y]:N = 18). Solicited local (SLS)
and general (SGS) symptoms, adverse events (AE) and seri-
ous AE (SAEs) were recorded.
Considering a 50 days follow-up period, injection site
pain was the most frequent SLS in both H5N1/AS and con-
trol groups (30/51 vs. 7/18 for 3-5y children; 44/51 vs. 12/18
for 6-9y children), with grade-3 pain in 2/51 children from
the H5N1/AS-[3—5y] group vs. 0 in the Control-[3—5y] group
and in 5 children from the H5N1/AS-[6—9y] group vs. 0 in
the Control-[6—9y] group. SGS were more frequent in the
H5N1/AS group. Grade-3 SGS were reported in 4/51 chil-
dren in the H5N1/AS-[3—5y] group (2 fever>39.1 ◦C, 2 losses
of appetite, 1 drowsiness) and in 0/18 in the correspond-
ing control group. For the 6-9y group, grade-3 SGS were
reported in 4/51 children in the H5N1/AS (2 headaches, 1
gastrointestinal disorder, 1 myalgia) and in 1/18 in the cor-
responding Control group (1 fever>39.1 ◦C). Most symptoms
lasted 1-2 days with no increase of duration or severity with
the second dose. No distinct pattern of symptomatology was
noted. No SAEs were reported.
In children aged 3—9 years, the candidate H5N1 AS-
adjuvanted vaccine did not raise any safety concerns and
the reactogenicity proﬁle was clinically acceptable.
doi:10.1016/j.ijid.2008.05.364
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Prepandemic H5N1 vaccines should be antigen-sparing,
have acceptable reactogenicity and offer cross-reactive
immunity to non-vaccine strains. Most clinical studies
have evaluated clade 1 strains which infected humans in
2004—2005, while clade 2 strains have infected humans since
2005. We evaluated two H5N1 vaccine candidates made with
a clade 2.1 strain.
The vaccine candidates, produced at 2 sites (Dres-
den [D], Quebec [Q]) by 2 distinct processes, were
made with A/Indonesia/5/2005 (clade 2.1) antigens.
Adults (18—64 years) were vaccinated twice, 21 days
apart, with 3.8g of hemagglutinin (HA) with an oil-in-
water emulsion-based Adjuvant System (AS) or without
(control). 150 subjects received AS-adjuvanted D- or
Q-antigens, while 75 control subjects received a non-
